Cipla reported INR74.04B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 2.44M 151K Jun/2026
Bio Path 0 0 Mar/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 74.04B 2.85B Sep/2026
Dr.Reddys Laboratories INR 86.98B 6.27B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sun Pharmaceuticals INR 161.99B 8.99B Sep/2026
TherapeuticsMD USD 234K 79K Jun/2024
UPL INR 118.6B 16.79B Sep/2026